Patents by Inventor Richard E. Gammans

Richard E. Gammans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of progressive neurodegenerative disease with ibudilast
    Patent number: 11944607
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: April 2, 2024
    Assignee: MediciNova, Inc.
    Inventors: Michael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
  • TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST
    Publication number: 20220168283
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Application
    Filed: July 2, 2021
    Publication date: June 2, 2022
    Applicant: MediciNova, Inc.
    Inventors: Michael E. Kalafer, Kenneth W. LOCKE, Kazuko MATSUDA, Richard E. GAMMANS
  • Treatment of progressive neurodegenerative disease with ibudilast
    Patent number: 11083713
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: August 10, 2021
    Assignee: MediciNova, Inc.
    Inventors: Michael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
  • Formulations of n-acetylcysteine and uses thereof
    Patent number: 11020354
    Abstract: Disclosed herein are compositions comprising a first compound that is N-acetylcysteine or a salt thereof, optionally a second compound that is a pharmaceutically acceptable compound capable of forming a radical adduct; and a coating layer encapsulating at least the first compound. Also disclosed are methods of use and manufacture.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: June 1, 2021
    Assignee: Otologic Pharmaceuticals, Inc.
    Inventor: Richard E. Gammans
  • TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST
    Publication number: 20200093805
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Application
    Filed: May 1, 2019
    Publication date: March 26, 2020
    Applicant: MediciNova, Inc.
    Inventors: Michael E. KALAFER, Kenneth W. LOCKE, Kazuko MATSUDA, Richard E. GAMMANS
  • FORMULATIONS OF N-ACETYLCYSTEINE AND USES THEREOF
    Publication number: 20180200192
    Abstract: Disclosed herein are compositions comprising a first compound that is N-acetylcysteine or a salt thereof, optionally a second compound that is a pharmaceutically acceptable compound capable of forming a radical adduct; and a coating layer encapsulating at least the first compound. Also disclosed are methods of use and manufacture.
    Type: Application
    Filed: January 18, 2018
    Publication date: July 19, 2018
    Applicant: Otologic Pharmaceutics, Inc.
    Inventor: Richard E. Gammans
  • TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST
    Publication number: 20170020851
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Applicant: MediciNova, Inc.
    Inventors: Michael E. KALAFER, Kenneth W. LOCKE, Kazuko MATSUDA, Richard E. GAMMANS
  • TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST
    Publication number: 20170014390
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Application
    Filed: March 23, 2016
    Publication date: January 19, 2017
    Applicant: MediciNova, Inc.
    Inventors: Michael E. KALAFER, Kenneth W. LOCKE, Kazuko MATSUDA, Richard E. GAMMANS
  • Treatment of amyotrophic lateral sclerosis (ALS) with ibudilast
    Patent number: 9314452
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: April 19, 2016
    Assignee: MediciNova, Inc.
    Inventors: Michael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
  • Treatment of progressive neurodegenerative disease with ibudilast
    Patent number: 9114136
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: August 25, 2015
    Assignee: MEDICINOVA, INC.
    Inventors: Michael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
  • TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST
    Publication number: 20150011581
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Application
    Filed: September 19, 2014
    Publication date: January 8, 2015
    Applicant: MediciNova, Inc.
    Inventors: Michael E. KALAFER, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
  • TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST
    Publication number: 20140171463
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicant: MediciNova, Inc.
    Inventors: Michael E. KALAFER, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
  • Treatment of progressive neurodegenerative disease with ibudilast
    Patent number: 8338453
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2 -isopropylpyrazolo[1,5-a]pyridine).
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: December 25, 2012
    Assignee: Medicinova, Inc.
    Inventors: Michael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
  • TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST
    Publication number: 20120214839
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Application
    Filed: February 22, 2012
    Publication date: August 23, 2012
    Inventors: Michael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
  • Treatment of progressive neurodegenerative disease with ibudilast
    Patent number: 8138201
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: March 20, 2012
    Assignee: MediciNova, Inc.
    Inventors: Michael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
  • IBUDILAST AND IMMUNOMODULATORS COMBINATION
    Publication number: 20100260755
    Abstract: The invention contemplates methods and compositions for treating multiple sclerosis including the administration of a PDE inhibitor and at least one immunomodulator comprising mitoxantrone, natalizumab, fingolimod, laquinimod, cladribine, dimethylfumarate or a mixture comprising synthetic polypeptide analogs of myelin basic protein, including alanine, glutamic acid, lysine, and tyrosine amino acid residues, in a therapeutically effective amount. A preferred PDE inhibitor includes ibudilast.
    Type: Application
    Filed: April 7, 2010
    Publication date: October 14, 2010
    Inventors: Richard E. GAMMANS, Kenneth W. Locke, Michael E. Kalafer
  • TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST
    Publication number: 20090062330
    Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
    Type: Application
    Filed: July 8, 2008
    Publication date: March 5, 2009
    Inventors: Michael E. KALAFER, Kenneth W. LOCKE, Kazuko MATSUDA, Richard E. GAMMANS
  • Benzanilide derivative
    Patent number: 4618680
    Abstract: 4-Hydroxy-3-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]-phenyl]benzamide is an antiarrhythmic agent having relatively low toxicity and increased duration of action.
    Type: Grant
    Filed: November 27, 1981
    Date of Patent: October 21, 1986
    Assignee: Mead Johnson & Company
    Inventors: Robert F. Mayol, Richard E. Gammans
  • Antidepressant 1,2,4-triazolone compounds
    Patent number: 4613600
    Abstract: 2-[3-[4-(3-Halophenyl)-1-piperazinyl]propyl]-5-(1-hydroxyethyl)-2,4-dihydro -[4-phenoxyalkyl-3H-1,2,4-triazol-3-ones and closely related compounds are psychotropic agents having promise as antidepressants by virtue of their receptor site binding affinity profiles and animal pharmacology.
    Type: Grant
    Filed: September 30, 1983
    Date of Patent: September 23, 1986
    Assignee: Mead Johnson & Company
    Inventors: Richard E. Gammans, David W. Smith, Joseph P. Yevich
  • Benzanilide derivative
    Patent number: 4332803
    Abstract: 4-Hydroxy-3-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]-phenyl]benzamide is an antiarrhythmic agent having relatively low toxicity and increased duration of action.
    Type: Grant
    Filed: September 18, 1980
    Date of Patent: June 1, 1982
    Assignee: Mead Johnson & Company
    Inventors: Robert F. Mayol, Richard E. Gammans